选择性CD28拮抗剂与雷帕霉素协同预防NOD小鼠自发性自身免疫性糖尿病
在NOD小鼠1型糖尿病模型中,PV1-PEG(10 mg/kg腹腔注射,每周两次)联合雷帕霉素(1 mg/kg腹腔注射,每周两次)4周可有效控制10周龄小鼠自身免疫性糖尿病的进展,减少T细胞活化及向胰腺迁移;雷帕霉素单药无效,PV1-PEG单药在4、6或10周龄起始均无效;延长PV1-PEG给药10周加速糖尿病发展并伴外周Treg稳态受损,联合治疗未见此效应。
要点
- PV1-PEG联合雷帕霉素4周可控制10周龄NOD小鼠糖尿病进展。
- 雷帕霉素单药及PV1-PEG单药(4、6或10周龄起始)均无效。
- 延长PV1-PEG给药10周加速糖尿病并伴外周Treg稳态受损,联合治疗无此效应。
核心结论
- CD28拮抗剂与雷帕霉素以互补方式限制T细胞活化、胰岛浸润及糖尿病发展,为自身免疫性糖尿病治疗提供新视角,并支持联合CD28拮抗剂与mTOR通路拮抗剂方案的治疗潜力。
研究设计与样本
- NOD小鼠模型研究,比较PV1-PEG(10 mg/kg腹腔注射,每周两次)、雷帕霉素(1 mg/kg腹腔注射,每周两次)及两药联合,分析糖尿病发生率、胰岛浸润及自身反应性T细胞反应。
主要发现
- 4周PV1-PEG联合雷帕霉素有效控制10周龄NOD小鼠自身免疫性糖尿病进展,减少T细胞活化及向胰腺迁移。
- 雷帕霉素单药无效,PV1-PEG单药在4、6或10周龄起始均无效。
- 延长PV1-PEG给药10周加速糖尿病发展,伴外周Treg稳态受损;联合治疗未观察到此效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The CD28/B7 interaction is critical for both effector T cell activation and forkhead box P3 (FOXP3)+ regulatory T cell (Treg) generation and homeostasis, which complicates the therapeutic use of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-immunoglobulin fusion protein (CTLA-4Ig) in autoimmunity. Here, we evaluated the impact of a simultaneous and selective blockade of the CD28 and mammalian target of rapamycin (mTOR) pathways in the NOD mouse model of type 1 diabetes. METHODS: NOD mice were treated with PEGylated anti-CD28 Fab' antibody fragments (PV1-polyethylene glycol [PEG], 10 mg/kg i.p., twice weekly), rapamycin (1 mg/kg i.p., twice weekly) or a combination of both drugs. Diabetes incidence, pancreatic islet infiltration and autoreactive T cell responses were analysed. RESULTS: We report that 4 week administration of PV1-PEG combined with rapamycin effectively controlled the progression of autoimmune diabetes in NOD mice at 10 weeks of age by reducing T cell activation and migration into the pancreas. Treatment with rapamycin alone was without effect, as was PV1-PEG monotherapy initiated at 4, 6 or 10 weeks of age. Prolonged PV1-PEG administration (for 10 weeks) accelerated diabetes development associated with impaired peripheral Treg homeostasis. This effect was not observed with the combined treatment. CONCLUSIONS/INTERPRETATION: CD28 antagonist and rapamycin treatment act in a complementary manner to limit T cell activation and infiltration of pancreatic islets and diabetes development. These data provide new perspectives for the treatment of autoimmune diabetes and support the therapeutic potential of protocols combining antagonists of CD28 (presently in clinical development) and the mTOR pathway.
引用
- Besançon A, Goncalves T, Valette F, et al. A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice. Diabetologia. 2018. PMID: 29845333. doi:10.1007/s00125-018-4638-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。